Difference between revisions of "Trastuzumab-anns (Kanjinti)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Neutral chemotherapy" to "Category:Neutral") Tags: mobile edit mobile web edit |
m |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2019-06-13: Initial approval for the treatment of [[Biomarkers#HER2|HER2]] [[Biomarkers#Overexpression|overexpressing]] [[breast cancer]]. |
| − | + | *2019-06-13: Initial approval for the treatment of [[Biomarkers#HER2|HER2]] [[Biomarkers#Overexpression|overexpressing]] metastatic [[Gastric_cancer|gastric or gastroesophageal junction adenocarcinoma]]. | |
| − | * | ||
==Also known as== | ==Also known as== | ||
| Line 27: | Line 26: | ||
[[Category:Protein expression-specific medications]] | [[Category:Protein expression-specific medications]] | ||
| − | + | ||
[[Category:Anti-HER2 antibodies]] | [[Category:Anti-HER2 antibodies]] | ||
[[Category:Neutral]] | [[Category:Neutral]] | ||
Latest revision as of 17:04, 9 May 2023
Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.
General information
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
To be completed
History of changes in FDA indication
- 2019-06-13: Initial approval for the treatment of HER2 overexpressing breast cancer.
- 2019-06-13: Initial approval for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Also known as
- Brand name: Kanjinti